Trevi Therapeutics (NASDAQ: TRVI) bets everything on two Phase 3 chronic cough trials

Trevi Therapeutics is a small biotech with one big idea: that a reformulated opioid-derived drug can finally treat the relentless cough that torments patients with a deadly lung disease. The New Haven company is developing Haduvio, an oral extended-release form of nalbuphine, for chronic cough in idiopathic pulmonary fibrosis and related conditions, and it has just won FDA alignment to launch a pair of pivotal Phase 3 trials. The reason the ticker draws a steady retail crowd is the classic biotech setup: a stock up about 71 percent over the past year, no revenue, a roughly US$1.5 billion valuation, and a future that rests almost entirely on trial readouts still more than a year away. For an investor arriving from a forum, the question is whether the science and the catalyst calendar justify owning a company whose product may not reach the market until the end of the decade.

What does Trevi Therapeutics do and how does Haduvio aim to treat chronic cough in IPF?

Trevi Therapeutics is a clinical-stage biopharmaceutical company with a single lead asset, Haduvio, the brand name for oral nalbuphine extended-release. It is being developed for chronic cough across three settings: idiopathic pulmonary fibrosis, or IPF, the lead indication, plus non-IPF interstitial lung disease and refractory chronic cough. The company was founded in 2011 and is led by president and chief executive Jennifer Good.

The scientific pitch rests on how the drug works. Nalbuphine is an opioid-derived molecule, and Trevi describes Haduvio as having a dual mechanism that acts on both the central and peripheral parts of the cough reflex, which the company argues could make it more effective than agents that target only one pathway. Chronic cough in IPF is a genuinely underserved problem, because the cough is severe, persistent and currently has no approved therapy, so a drug that works would address a clear unmet need.

The implication for an investor is both the appeal and the catch. A first approved treatment in a disease with nothing on the market is a powerful commercial proposition, but the company has no revenue, no approved product, and everything depends on a single drug candidate succeeding in late-stage trials. The opioid heritage of the molecule also means it will face the prescriber and payer scrutiny that any opioid-class therapy attracts, even one designed for a non-pain indication.

Why is the FDA-aligned Phase 3 OCEAN program the catalyst that defines the TRVI story?

The event that reshaped the story was regulatory. In early 2026, Trevi completed an End-of-Phase 2 meeting with the FDA and gained alignment on the design of its pivotal program for IPF-related chronic cough, converting years of earlier-stage work into a defined registrational path. That alignment matters because it removes a major uncertainty: the company now knows what the regulator expects to see for a potential approval.

The program itself is concrete. Trevi plans to run two pivotal Phase 3 trials, known as OCEAN 1 and OCEAN 2, in parallel, with the first starting in the second quarter of 2026 and the second following later in the year. Both are randomized, double-blind, placebo-controlled global studies testing a 54 milligram twice-daily dose, using objective 24-hour cough frequency as the primary endpoint, with patients randomized two-to-one against placebo. Alongside these, the company is starting a Phase 2b trial called LAKE in refractory chronic cough this quarter. The key dates investors are circling are the data readouts, expected in the second half of 2027 and the first half of 2028.

The implication is that the nature of the catalyst has changed. The near-term story is no longer about incremental Phase 2 updates but about executing these pivotal trials cleanly and, eventually, delivering positive data. That sharpens the risk and reward: a successful readout would validate the whole thesis and open a path to approval, while the long wait until 2027 means there is an extended stretch where the stock trades on expectation rather than results.

What happened to the stock when Trevi chose to run two pivotal Phase 3 trials in parallel?

The market’s reaction to good news was revealing. When Trevi announced the FDA alignment and its decision to run two Phase 3 trials in parallel, the stock actually fell, dropping around 12 percent on the End-of-Phase 2 news and about 17 percent on the parallel-trials decision. On paper this was progress, yet shares sold off, a pattern familiar to anyone who trades clinical-stage biotech.

The reason lies in the trade-offs the decision created. Running two pivotal trials at once accelerates the timeline toward a potential approval and strengthens the eventual data package, but it also increases the company’s cash needs and execution risk. For a business with no revenue and a history of raising money through share sales, a more ambitious and expensive program raises the prospect of further dilution, and the market priced that in immediately even as it acknowledged the strategic logic.

The implication is that TRVI does not trade cleanly on whether news is good or bad, but on how that news shifts the balance of probability, cost and time. A positive regulatory step that also implies a bigger spend can still send the stock down, which is exactly why the average reaction to its clinical announcements has been a double-digit move in either direction. Investors should expect volatility around every milestone, not a simple up-on-good, down-on-bad response.

How large is the chronic cough opportunity across IPF, non-IPF ILD and refractory chronic cough?

The bull case scales well beyond the lead indication. Trevi is targeting three chronic cough markets, starting with IPF cough and expanding into non-IPF interstitial lung disease and refractory chronic cough, all of which it describes as large and largely untreated. Stacking these indications is what turns a niche respiratory drug into a potential franchise, and at a key opinion leader event the company and supportive analysts pointed to peak sales potential in the billions of dollars across the combined indications.

The strategic logic is that one molecule can address several related conditions, spreading development risk and broadening the eventual commercial footprint. Adding the non-IPF ILD indication, for example, is framed as roughly doubling the opportunity, and the refractory chronic cough market is far larger still in patient numbers. The company has also outlined a focused specialty respiratory commercial strategy, the kind a smaller biotech can execute without a vast salesforce.

The caveat is that peak sales estimates are projections built on success that has not yet happened. Each indication requires its own positive trials, regulatory clearance and commercial uptake, and the larger refractory chronic cough market is also the most competitive. A multibillion-dollar opportunity is real only if the drug works across these settings and wins both approval and physician adoption, so the headline market size should be read as the prize, not the expectation.

How is Trevi Therapeutics funding years of trials before Haduvio could ever reach the market?

Funding is the practical question that decides whether a clinical-stage company survives to its catalysts. Trevi addressed this directly in April 2026 with a follow-on stock offering that raised net proceeds of about US$162 million, which the company says extends its cash runway into 2030. Crucially, management states this is enough to fund the lead IPF program potentially all the way through FDA approval, as well as the planned Phase 2b trials, which removes the most immediate financing worry.

That runway is a genuine strength for a biotech at this stage. Many clinical companies are forced to raise money from a position of weakness right before key data, whereas Trevi has secured years of funding ahead of its pivotal readouts, and institutional investors own the overwhelming majority of the stock. A long runway lets management focus on execution rather than survival.

The implication, however, is that dilution is part of the deal and likely to continue. The company funded itself by issuing new shares, it has proposed doubling its authorized share count to 400 million to create headroom, and the chief financial officer has indicated it will seek additional funding for extended trials and major inflection points. The IPF program may be covered, but expanding into the other indications and eventually commercialising the drug will require more capital, and existing shareholders should expect their stake to be diluted along the way.

What are the clinical, dilution and competition risks facing Trevi Therapeutics shareholders?

The dominant risk is binary and unavoidable: the Phase 3 trials could fail. Chronic cough endpoints can be difficult, placebo responses are notoriously high in cough studies, and any disappointing efficacy or safety signal in the 2027 and 2028 readouts would severely damage the investment case for a company whose entire value rests on this one drug. With no other meaningful asset and no revenue, there is little to cushion a setback.

Dilution and timeline are the next layers. The long wait until pivotal data means years of cash burn and expectation-driven trading, and the funding strategy guarantees more share issuance over time, which weighs on per-share value even when the science progresses. The opioid-derived nature of nalbuphine adds a further dimension, since opioid-class therapies can face additional regulatory, labelling and commercial friction regardless of the target indication, which could complicate adoption even after approval.

Competition rounds out the picture. The chronic cough field, especially refractory chronic cough, has drawn interest from larger pharmaceutical companies pursuing their own mechanisms, so Trevi may not have these markets to itself by the time it arrives. None of these risks is hidden, and the strong cash position mitigates the financing one, but together they explain why a stock with bullish analyst targets still trades with such volatility. This is a high-risk, high-reward clinical bet in its purest form.

Why do retail biotech investors keep trading TRVI around every trial and FDA milestone?

Trevi has the profile that the retail biotech community loves to trade. It pairs a clear, sympathetic medical story with a well-defined catalyst calendar, and its shares move sharply on every FDA meeting, trial start and data event, with an average reaction in the mid-teens percent. The stock has climbed about 71 percent over the past year and trades near the top of its 52-week range, which runs from around US$5 to roughly US$16, and options activity around the name has at times been unusually heavy.

The appeal is the combination of upside and structure. Analysts are broadly positive, with a strong-buy consensus and an average price target well above the current price near US$20, and individual targets ranging up to the high US$20s and beyond, which gives the bull case a number to rally around. The peak-sales potential across multiple indications offers a big-picture story, while the trial timeline gives traders specific dates to position around.

The flip side is the volatility that defines the category. As the reaction to the Phase 3 decision showed, even favourable news can trigger sharp drops when it implies more spending, and the long gap until pivotal readouts leaves the stock exposed to sentiment swings and financing announcements. With the OCEAN trials starting now and data not due until 2027, there is a long road of milestones to trade, but anyone holding through it is exposed to the all-or-nothing nature of late-stage clinical development, where a single readout can reprice the entire company.

Key takeaways for retail investors weighing Trevi Therapeutics (NASDAQ: TRVI)

• Trevi Therapeutics is a clinical-stage biotech whose entire value rests on Haduvio, an oral extended-release form of nalbuphine, for chronic cough in IPF and related lung conditions, with no approved product or revenue.
• The defining catalyst is the FDA-aligned Phase 3 OCEAN program, with two pivotal trials starting in 2026 but data readouts not expected until the second half of 2027 and first half of 2028.
• The stock has a habit of falling on apparently good news, dropping double digits when the parallel Phase 3 decision raised the prospect of higher costs and dilution.
• The opportunity spans IPF, non-IPF ILD and refractory chronic cough, with billions in cited peak sales potential, but those figures depend on trial success and approval that have not yet happened.
• An April 2026 raise of about US$162 million extends the cash runway into 2030 and potentially funds the lead program through approval, a real strength, though further dilution is likely.
• Key risks are binary trial failure, ongoing dilution, the regulatory and commercial scrutiny that comes with an opioid-derived drug, and competition from larger players in chronic cough.
• This is a high-risk, high-reward clinical bet, up about 71 percent in a year and trading near US$15 within a 52-week range of roughly US$5 to US$16, where a single readout could reprice the whole company.